Peer reviewed
Once-weekly semaglutide in adults with overweight or obesity
Randomized STEP 1 trial of semaglutide in adults with overweight or obesity.
New England Journal of MedicinePublished Feb 10, 2021Accessed Jul 12, 2026
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-semaglutide-step1-2021-video
Source usage
Linked from 6 pages
Video audit
Dr. Explains Why Retatrutide is KING of Fat Loss Peptides
Video auditHow Do Ozempic, Mounjaro & Other GLP-1 Agonists Work? | Dr. Zachary Knight & Dr. Andrew Huberman
Video auditOzempic is a game-changer. Here's how it works.
Video auditWhat Ozempic & Weight Loss Drugs Really Do to the Body
Video auditDoctors explain how Wegovy and Ozempic work | 60 Minutes
Video auditWhat Is a GLP-1 Agonist, and How Does It Work?
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.